TLR8 Agonist VTX-2337: Clinical Trials

3 trials of TLR8 Agonist VTX-2337, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Terminated 1

Follow TLR8 Agonist VTX-2337: new trials by email Literature Review of TLR8 Agonist VTX-2337 trials Research Report on TLR8 Agonist VTX-2337

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 1TerminatedMayo Clinic42016-02-052018-09-05
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase 1CompletedUniversity of Washington132011-06-012015-03-05
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor
Phase 1CompletedGynecologic Oncology Group202011-03-012014-12-25

Conditions studied

Breast Neoplasms (1)  ·  Brenner Tumor (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Colorectal Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Melanoma (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Salivary Gland Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Tongue Neoplasms (1)

Sponsors

Gynecologic Oncology Group (1)  ·  Mayo Clinic (1)  ·  University of Washington (1)

Countries

United States (3)

Top investigators

Bradley Monk (1)  ·  Laura Chow (1)  ·  Peter Cohen (1)

Results publications

PMID 26928328

NIH funding

P30CA015083 (1), P30CA015704 (1), U10CA027469 (1)